The COVID-19 Pandemic – Webinars and Online Events

In this webinar, Dr. Alfredo Hildalgo Miranda will demonstrate the potential and flexibility of Oxford Nanopore Technologies’ sequencing platforms in cancer and infectious disease research.

This webinar will focus on recent trends in human influenza infection, including how the current respiratory season compares with recent years.

Recent years have witnessed a sea-change in how laboratory tests have been employed to diagnose, monitor, and manage viral infections.

In recent past respiratory seasons, the world witnessed a “tripledemic” of Influenza (flu), SARS-CoV-2 (COVID-19), and Respiratory Syncytial Virus (RSV). The 2024-25 landscape will likely be different, with new virus variants, new vaccines and treatments, like the game-changing antibody that protects children from RSV. The healthcare and public health community have also learned some valuable lessons going forward with the ever-evolving respiratory agents.

In this presentation, Dr. Rodney Rohde will discuss the primary microbiology, epidemiology, control, prevention, vulnerable populations, the importance of laboratory validation, and the benefits of molecular-based testing of these three primary respiratory season pathogens.

Key advances will be highlighted across the field of immuno-oncology. Hear a cross-section of experts discuss their research with a focus on basic research and a broad range of established and novel immunotherapeutics.

This webinar explores how a next-generation automated ELISA technique can profile the dysregulated host response to COVID-19 in association with viral load in plasma.

The COVID-19 pandemic significantly affected the spread of respiratory pathogens, but their circulation is now returning to pre-pandemic levels.

Meaningful biomarker studies that account for genetic, environmental and lifestyle variation, or comprise of complex signatures from multiple proteins, require large cohorts – too large for the current proteomics discovery platforms.

In this webinar, Dr. Jonathan Schmitz will provide a broad overview of PCR in diagnostic microbiology, with particular emphasis on the challenges that can face the development of new assays and impact their clinical actionability. Many of these issues - while hardly unique to SARS-CoV-2- can be highlighted by the evolving dynamics of this virus over the past three years.

With the recent COVID-19 pandemic, quantitative polymerase chain reaction (qPCR) was adopted rapidly into clinical and point-of-care testing laboratories enabling prompt diagnostics, treatment and surveillance. qPCR remains the go-to method for microbial detection in areas including clinical, agricultural, veterinary and food safety diagnostics.